Akpan Uduak, Nwanja Esther, Ukpong Kufre-Abasi, Toyo Otoyo, Nwaokoro Pius, Sanwo Olusola, Gana Bala, Badru Titilope, Idemudia Augustine, Pandey Satish Raj, Khamofu Hadiza, Bateganya Moses
Achieving Health Nigeria Initiative (AHNi), Akwa Ibom, Nigeria.
FHI 360, Abuja, Nigeria.
Open Forum Infect Dis. 2022 Dec 15;9(12):ofac651. doi: 10.1093/ofid/ofac651. eCollection 2022 Dec.
This study assessed viral load (VL) testing and viral suppression following enhanced adherence counseling (EAC) among people with HIV (PWH) with suspected treatment failure and identified factors associated with persistent viremia.
We conducted a retrospective review of electronic medical records of PWH aged 15 years or older who had received antiretroviral therapy (ART) for at least 6 months as of December 2020 and had a high viral load (HVL; ≥1000 copies/mL) across 22 comprehensive HIV treatment facilities in Akwa Ibom State, Nigeria. Patients with HVL were expected to receive 3 EAC sessions delivered in person or virtually and repeat VL testing upon completion of EAC and after documented good adherence. At 6 months post-EAC enrollment, we reviewed the data to determine client uptake of 1 or more EAC sessions, completion of 3 EAC sessions, a repeat viral load (VL) test conducted post-EAC, and persistent viremia with a VL of ≥1000 copies/mL. Selected sociodemographic and clinical variables were analyzed to identify factors associated with persistent viremia using SPSS, version 26.
Of the 3257 unsuppressed PWH, EAC uptake was 94.8% (n = 3088), EAC completion was 81.5% (2517/3088), post-EAC VL testing uptake was 75.9% (2344/3088), and viral resuppression was 73.8% (2280/3088). In multivariable analysis, those on ART for <12 months ( ≤ .001) and those who completed EAC within 3 months ( = .045) were less likely to have persistent viremia.
An HVL resuppression rate of 74% was achieved, but EAC completion was low. Identification of the challenges faced by PWH with a higher risk of persistent viremia is recommended to optimize the potential benefit of EAC.
本研究评估了疑似治疗失败的艾滋病毒感染者(PWH)在接受强化依从性咨询(EAC)后的病毒载量(VL)检测和病毒抑制情况,并确定了与持续病毒血症相关的因素。
我们对2020年12月时年龄在15岁及以上、接受抗逆转录病毒治疗(ART)至少6个月且在尼日利亚阿夸伊博姆州22个综合艾滋病毒治疗机构中病毒载量较高(HVL;≥1000拷贝/毫升)的PWH的电子病历进行了回顾性研究。HVL患者预计接受3次亲自或通过虚拟方式进行的EAC咨询,并在EAC咨询完成后以及记录显示依从性良好后重复进行VL检测。在EAC登记后6个月,我们审查数据以确定患者接受1次或更多次EAC咨询的情况、完成3次EAC咨询的情况、EAC咨询后进行的重复病毒载量(VL)检测情况以及VL≥1000拷贝/毫升的持续病毒血症情况。使用SPSS 26版对选定的社会人口统计学和临床变量进行分析,以确定与持续病毒血症相关的因素。
在3257名未实现病毒抑制的PWH中,EAC咨询的接受率为94.8%(n = 3088),EAC咨询的完成率为81.5%(2517/3088),EAC咨询后VL检测的接受率为75.9%(2344/3088),病毒重新抑制率为73.8%(2280/3088)。在多变量分析中,接受ART治疗<12个月的患者(P≤.001)以及在3个月内完成EAC咨询的患者(P = .045)发生持续病毒血症的可能性较小。
实现了74%的HVL重新抑制率,但EAC咨询的完成率较低。建议识别持续病毒血症风险较高的PWH所面临的挑战,以优化EAC咨询的潜在益处。